Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia

Leukemia

Volumn 20, Issue 2, 2006, Pages 247-253

  Meyer Monard, S ^a   Parlier, V ^b   Passweg, J ^a   Muhlematter D ^b   Hess, U ^c   Bargetzi, M ^d   Kuhne T ^e   Cabrol, C ^f   Gratwohl, A ^a   Jotterand, M ^b   Tichelli, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d CANTONAL HOSPITAL AARAU   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Broad molecular screening; Cytogenetics; Diagnosis; Genetic risk assignment; Leukemia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENETIC RISK; GENETIC SCREENING; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; T CELL LEUKEMIA; WORLD HEALTH ORGANIZATION;

EID: 31444444810     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404044     Document Type: Article

References (19)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organisation Classification of Tumors. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
3. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.
4. Tallman MS, Rowe JM. Acute promyelocytic leukemia: A paradigm for differentiation therapy with retinoic acid. Blood Rev 1994; 8: 70-78.
5. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
6. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
7. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998; 92: 574-588.
8. Strehl S, Konig M, Mann G, Haas OA. Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. Blood 2001; 97: 805-808.
9. Elia L, Mancini M, Moleti L, Meloni G, Buffolino S, Krampera M et al. A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: A clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica 2003; 88: 275-279.
10. Zach O, Kessler B, Stammler M, Girschikofski M, Krieger O, Kasparu H et al. Comparison of a multiplex RT-PCR assay with cytogenetic analyses in adult hematologic neoplasms. Hematol J 2004; 5 (Suppl 2): 77.
11. Castagné C, Mühlematter D, van Melle G, Gachoud V, Jotterand Bellomo M. Effect of conditioned media, nutritive elements, and mitotic synchronization on the accuracy of the cytogenetic analysis in acute nonlymphocytic leukemia patients presenting with inv(16)/t(16;16) or t(15;17). Cancer Genet Cytogenet 1997; 94: 106-112.
12. Jotterand Bellomo M, Parlier V, Mühlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992; 59: 138-160.
13. Mitelman F. An international system for human cytogenetic nomenclature. Basel: Karger, 1995.
14. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
15. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
16. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 2004; 22: 1087-1094.
17. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17: 3767-3775.
18. de Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial. Br J Haematol 2000; 111: 801-806.
19. Bienz M, Ludwig M, Mueller BU, Leibundgut EO, Ratschiller D, Solenthaler M et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416-1424.